Answers are grounded in this paper and cite their sources.
Cohort study reveals effects of nintedanib on treatment continuity in systemic sclerosis patients, suggesting need for careful monitoring.
Adverse effects frequently led to treatment interruptions in SSc-ILD patients. Older age and lower BMI were predictors of interruption, while no clear predictors of permanent discontinuation were identified. Most patients resumed treatment, highlighting the need for close monitoring and supportive care to manage side effects and maintain treatment continuity.
No takes yet. Share an insight, caveat, or question.
Kaenmuang et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: